Cyclooxygenase-2 Expression in Retinoblastoma: An Immunohistochemical Analysis

REFERENCES

• Hahnfeldt P, Panigrahy D, Folkman J, et al. Tumor development under angiogenic signaling: A dynamical theory of tumor growth, treatment response, and postvascular dormancy. Cancer Res 1999;59:4770–4775.
   PubMed Web of Science ®Google Scholar
• Giavazzi R, Sennino B, Coltrini D, et al. Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis. Am J Pathol 2003;162:1913–1926.
   PubMed Web of Science ®Google Scholar
• Joo YE, Kim HS, Min SW, et al. Expression of cyclooxygenase-2 protein in colorectal carcinomas. Int J Gastrointest Cancer 2002;31:147–154.
   PubMedGoogle Scholar
• Chwirot BW, Kuźbicki Ł. Cyclooxygenase-2 (COX-2): First immunohistochemical marker distinguishing early cutaneous melanomas from benign melanocytic skin tumours. Melanoma Res 2007;17:139–145.
   Google Scholar
• Koshiba T, Hosotani R, Miyamoto Y, et al. Immunohistochemical analysis of cyclooxygenase-2 expression in pancreatic tumors. Int J Pancreatol 1999;26:69–76.
   PubMedGoogle Scholar
• Zhi H, Wang L, Zhang J, et al. Significance of COX-2 expression in human esophageal squamous cell carcinoma. Carcinogenesis 2006;27:1214–1221.
   PubMed Web of Science ®Google Scholar
• Ragel BT, Jensen RL, Gillespie DL, et al. Ubiquitous expression of cyclooxygenase-2 in meningiomas and decrease in cell growth following in vitro treatment with the inhibitor celecoxib: Potential therapeutic application. J Neurosurg 2005;103:508–517.
   PubMed Web of Science ®Google Scholar
• Watanabe O, Shimizu T, Imamura H, et al. Expression of cyclooxygenase-2 in malignant and benign breast tumors. Anticancer Res 2003;23:3215–3221.
   PubMed Web of Science ®Google Scholar
• Peng JP, Su CY, Chang HC, et al. Overexpression of cyclo-oxygenase 2 in squamous cell carcinoma of the hypopharynx. Hum Pathol 2002;33:100–104.
   PubMed Web of Science ®Google Scholar
• Sumi T, Ishiko O, Yoshida H, et al. Expression of cyclooxygenase-2 in ovarian mature cystic teratomas with malignant transformation. Int J Mol Med 2001;8:495–498.
   Google Scholar
• Shirahama T, Sakakura C. Overexpression of cyclooxygenase-2 in squamous cell carcinoma of the urinary bladder. Clin Cancer Res 2001;7:558–561.
   PubMed Web of Science ®Google Scholar
• Becker MR, Siegelin MD, Rompel R, et al. COX-2 expression in malignant melanoma: A novel prognostic marker? Melanoma Res 2009;19:8–16.
   PubMed Web of Science ®Google Scholar
• Urakawa H, Nishida Y, Naruse T, et al. Cyclooxygenase-2 overexpression predicts poor survival in patients with high-grade extremity osteosarcoma: A pilot study. Clin Orthop Relat Res 2009. [Epub ahead of print]
   Google Scholar
• Huh JW, Kim HR, Lee JH, et al. Comparison of cyclooxygenase-2 and CD44 mRNA expression in colorectal cancer and its relevance for prognosis. Virchows Arch 2009;454:381–387.
   Google Scholar
• Sackett MK, Bairati I, Meyer F, et al. Prognostic significance of cyclooxygenase-2 overexpression in glottic cancer. Clin Cancer Res 2008;14:67–73.
   Google Scholar
• Karim MM, Hayashi Y, Inoue M, et al. Cox-2 expression in retinoblastoma. Am J Ophthalmol. 2000;129:398–401.
   Google Scholar
• Souza Filho JP, Martins MC, Correa ZM, et al. The expression of cyclooxygenase 2 in retinoblastoma: Primary enucleated eyes and enucleation after conservative treatment. Am J Ophthalmol 2006;142:625–631.
   Google Scholar
• Tong CT, Howard SA, Shah HR, et al. Effects of celecoxib in human retinoblastoma cell lines and in a transgenic murine model of retinoblastoma. Br J Ophthalmol 2005;89:1217–1220.
   PubMed Web of Science ®Google Scholar
• Atchaneeyasakul L, Murphree AL. Retinoblastoma. In: SJ Ryan (Ed.). Retina. Volume One. 3rd ed. St. Louis: Mosby Inc, 2001; pp. 513–570.
   Google Scholar
• Garewal H, Ramsey L, Fass R, et al. Perils of immunohistochemistry: Variability in staining specificity of commercially available COX-2 antibodies on human colon tissue. Dig Dis Sci 2003;48:197–202.
   PubMed Web of Science ®Google Scholar
• Werner M. Advances in standardization of immunohistochemistry. Rev Esp Patol 1999;32:355–361.
   Google Scholar
• Half EE, Arber N. Chemoprevention of colorectal cancer: Two steps forward, one step back? Future Oncol 2006;2:697–704.
   PubMedGoogle Scholar
• Arber N, Eagle CJ, Spicak J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006;355:885–895.
   PubMed Web of Science ®Google Scholar
• Hawk E, Viner JL. The adenoma prevention with celecoxib and prevention of colorectal sporadic adenomatous polyps trials: Stepping stones to progress. Cancer Epidemiol Biomarkers Prev 2007;16:185–187.
   Google Scholar
• Swamy MV, Cooma I, Patlolla JM, et al. Modulation of cyclooxygenase-2 activities by the combined action of celecoxib and decosahexaenoic acid: Novel strategies for colon cancer prevention and treatment. Mol Cancer Ther 2004;3:215–221.
   PubMed Web of Science ®Google Scholar
• Brown PH, Subbaramaiah K, Salmon AP, et al. Combination chemoprevention of HER2/neu-induced breast cancer using a cyclooxygenase-2 inhibitor and a retinoid X receptor-selective retinoid. Cancer Prev Res (Phila Pa) 2008;1:208–214.
   Google Scholar
• Chow LW, Yip AY, Loo WT, et al. Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer. J Steroid Biochem Mol Biol 2008;111:13–17.
   PubMed Web of Science ®Google Scholar
• Mutter R, Lu B, Carbone DP, et al. A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer. Clin Cancer Res 2009;15:2158–2165.
   Google Scholar
• Gasparini G, Longo R, Sarmiento R, et al. Inhibitors of cyclo-oxygenase 2: A new class of anticancer agents? Lancet Oncol 2003;4:605–615.
   PubMed Web of Science ®Google Scholar
• Patel MI, Subbaramaiah K, Du B, et al. Celecoxib inhibits prostate cancer growth: Evidence of a cyclooxygenase-2-independent mechanism. Clin Cancer Res 2005;11:1999–2007.
   PubMed Web of Science ®Google Scholar
• Chuang HC, Kardosh A, Gaffney KJ, et al. COX-2 inhibition is neither necessary nor sufficient for celecoxib to suppress tumor cell proliferation and focus formation in vitro. Mol Cancer 2008;7:38.
   PubMedGoogle Scholar
• Li S, Tong Q, Zhang W, et al. Mechanism of growth inhibitory effects of cyclooxygenase-2 inhibitor-NS398 on cancer cells. Cancer Invest 2008;26:333–337.
   PubMed Web of Science ®Google Scholar
• Kim N, Kim CH, Ahn DW, et al. Anti-gastric cancer effects of celecoxib, a selective COX-2 inhibitor, through inhibition of Akt signaling. J Gastroenterol Hepatol 2009;24:480–487.
   PubMed Web of Science ®Google Scholar
• Eibl G, Takata Y, Boros LG, et al. Growth stimulation of COX-2-negative pancreatic cancer by a selective COX-2 inhibitor. Cancer Res 2005;65:982–990.
   PubMed Web of Science ®Google Scholar
• Augsburger JJ, Shields JA, Folberg R, et al. Fine needle aspiration biopsy in the diagnosis of intraocular cancer. Cytologic-histologic correlations. Ophthalmology 1985;92:39–49.
   PubMed Web of Science ®Google Scholar
• Chévez-Barrios P, Chintagumpala M, Mieler W, et al. Response of retinoblastoma with vitreous tumor seeding to adenovirus-mediated delivery of thymidine kinase followed by ganciclovir. J Clin Oncol 2005;23:7927–7935.
   PubMed Web of Science ®Google Scholar
• Faulkner-Jones BE, Foster WJ, Harbour JW, et al. Fine needle aspiration biopsy with adjunct immunohistochemistry in intraocular tumor management. Acta Cytol 2005; 49:297–308.
   PubMedGoogle Scholar